Skip to main content
OpenTrials

Clinical trial condition

Urologic Diseases

Explore clinical trials studying Urologic Diseases. Study availability and eligibility vary by location and protocol.

13,592 public trials 2,146 recruiting studies
Refine in advanced search Browse all conditions

Urologic Diseases trial results

Active, Not Recruiting

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

NCT05899049

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Beijing Cancer hospital-Renal carcinoma and melanoma ( Site 6000) Beijing, Beijing Municipality, China
  • Chongqing University Cancer Hospital ( Site 6009) Chongqing, Chongqing Municipality, China
  • SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 6003) Guangzhou, Guangdong, China
  • The First Affiliated Hospital of Guangzhou Medical University-Urology ( Site 6036) Guangzhou, Guangdong, China
View all 17 locations
View Trial Details
Active, Not Recruiting

BRINK (BRain In Kidney Disease) Memory Study 2.0

NCT04975464

Conditions
Alzheimer Disease, Arterial Occlusive Diseases, Arteriosclerosis, +41 more
Locations
  • Minneapolis VA Healthcare System Minneapolis, Minnesota, United States
  • Hennepin Healthcare Research Institute Minneapolis, Minnesota, United States
View Trial Details
Active, Not Recruiting

KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

NCT06342960

Conditions
Autoimmune Diseases, Connective Tissue Diseases, Female Urogenital Diseases, +13 more
Locations
  • Charite- Universitätsklinikum Berlin Berlin, Germany
  • Universitätsklinikum Carl Gustav Carus Dresden Dresden, Germany
  • Universitätsklinikum Düsseldorf Düsseldorf, Germany
  • Universitätsklinikum Erlangen Erlangen, Germany
View Trial Details
Active, Not Recruiting

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

NCT05938725

Conditions
Autoimmune Diseases, Connective Tissue Diseases, Female Urogenital Diseases, +13 more
Locations
  • Stanford University Medical Center Palo Alto, California, United States
  • University of Colorado Denver, Colorado, United States
  • University of Massachusetts Worcester Worcester, Massachusetts, United States
  • Northwell Health Great Neck, New York, United States
View Trial Details

Related conditions